These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 10716498)
1. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. Clayette P; Jorajuria S; Dormont D AIDS; 2000 Feb; 14(3):235-6. PubMed ID: 10716498 [No Abstract] [Full Text] [Related]
2. Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. Huisman MT; Smit JW; Schinkel AH AIDS; 2000 Feb; 14(3):237-42. PubMed ID: 10716499 [No Abstract] [Full Text] [Related]
3. Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins. Gimenez F; Fernandez C; Mabondzo A J Acquir Immune Defic Syndr; 2004 Jun; 36(2):649-58. PubMed ID: 15167283 [TBL] [Abstract][Full Text] [Related]
4. PharmGKB summary: Efavirenz pathway, pharmacokinetics. McDonagh EM; Lau JL; Alvarellos ML; Altman RB; Klein TE Pharmacogenet Genomics; 2015 Jul; 25(7):363-76. PubMed ID: 25966836 [No Abstract] [Full Text] [Related]
5. Protease inhibitors and mortality among children and adolescents infected with HIV-1. Barbaro G N Engl J Med; 2002 Mar; 346(13):1026-7; author reply 1026-7. PubMed ID: 11919316 [No Abstract] [Full Text] [Related]
6. Concentration-targeted therapy and the future of HIV management. Flexner CW; Piscitelli SC AIDS; 2002 Mar; 16 Suppl 1():S1-3. PubMed ID: 12035819 [No Abstract] [Full Text] [Related]
7. Reversal of abnormalities of neutrophil adhesion molecule expression in HIV infection following protease inhibitor therapy. Moore DA; Henderson D; Gotch F; Gazzard B AIDS; 1998 Oct; 12(15):2083-4. PubMed ID: 9814884 [No Abstract] [Full Text] [Related]
8. Hyperlipidemia associated with the use of protease inhibitors. Smith JH; Martin GJ; Decker CF Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432 [No Abstract] [Full Text] [Related]
12. Drug interactions and protease inhibitor therapy in the treatment of HIV/AIDS. Klaus BD; Grodesky MJ Nurse Pract; 1998 Feb; 23(2):102-4, 106. PubMed ID: 9513221 [No Abstract] [Full Text] [Related]
13. [Virologic levels for HIV before and after the introduction of protease inhibitors]. Molinero M; Solano C; Gomez-Cano M; Soriano V An Med Interna; 1998 Sep; 15(9):508-9. PubMed ID: 10079548 [No Abstract] [Full Text] [Related]
14. PharmGKB summary: atazanavir pathway, pharmacokinetics/pharmacodynamics. Alvarellos M; Guillemette C; Altman RB; Klein TE Pharmacogenet Genomics; 2018 May; 28(5):127-137. PubMed ID: 29517518 [No Abstract] [Full Text] [Related]
15. HIV-proteinase inhibitors in the management of HIV-infection. Moyle GJ; Barton SE J Antimicrob Chemother; 1996 Dec; 38(6):921-5. PubMed ID: 9023639 [No Abstract] [Full Text] [Related]
16. Benefits and risks of switching from protease inhibitors to nevirapine with stable background therapy in patients with low or undetectable viral load: a multicentre study. De Luca A; Baldini F; Cingolani A; Di Giambenedetto S; Zaccarelli M; Tozzi V; Ammassari A; Murri R; Antinori A AIDS; 2000 Jul; 14(11):1655-6. PubMed ID: 10983653 [No Abstract] [Full Text] [Related]
17. Liver fibrosis in HIV/hepatitis C coinfection: HIV protease inhibitors may be protective. James JS AIDS Treat News; 2001 Aug; (370):2-3. PubMed ID: 11570162 [No Abstract] [Full Text] [Related]
18. Acute clinical hepatitis in an HIV-seropositive hepatitis B carrier receiving protease inhibitor therapy. Mastroianni CM; Trinchieri V; Santopadre P; Lichtner M; Forcina G; D'Agostino C; Corpolongo A; Vullo V AIDS; 1998 Oct; 12(14):1939-40. PubMed ID: 9792403 [No Abstract] [Full Text] [Related]